NEUP · Neuphoria Therapeutics Inc.

3.71

USD

0.01 (0.27%)

21/09/2026 12:00:00 AM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

US$20.08M

0.00

EV/EBITDA

N/A

DIV Yield

0%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 21/09/2026 12:00:00 AM

Price Chart

Description

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

All-Consensus
HALO All

Key Fundamentals

EPS 3 yr Growth

2504.40%

EBITDA Margin

-779.10%

Operating Cashflow

-$12m

Free Cash Flow Return

-56.70%

ROIC

-61.70%

Interest Coverage

N/A

Quick Ratio

27.80

Performance

52 weeks range

Low 3.19 - 21.4

Trade Value (12mth)

US$699,997.00

1 week

-0.8%

1 month

-6.33%

YTD

-3.14%

1 year

-63.35%

All time high

264.00

Additional Data

Shares Outstanding (Fully Diluted)

HALO Sector

Healthcare

Next Company Report Date

01-Sep-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Weak

Earnings

Strong

Growth

Earnings

Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

Date	Event
24 July 26EDG
24 July 26EDG
27 May 26EDG
27 May 26EDG
15 May 26EDG

Key Stakeholders

Name	Title
Baselake Management LLC	Private Company
Robert Lipyanek	Individual
Merck & Co., Inc.	Public Company
Spyridon Papapetropoulos	Individual
Jane Ryan	Individual